Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in Ambrx Biopharma, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +1 vs. Q3 2021
- Shares held
- 16.8M
- +4.42M (+35.6%) vs. Q3 2021
- Total value
- $152.0M
- −$13.4M (−8.1%) vs. Q3 2021
- New holders
- 2
- 4 more added
- Sold out
- 1
- 5 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AMAM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 68 | $912.7M |
| Q3 2023 | 44 | $568.3M |
| Q2 2023 | 42 | $788.8M |
| Q1 2023 | 30 | $330.7M |
| Q4 2022 | 18 | $40.7M |
| Q3 2022 | 16 | $18.0M |
| Q2 2022 | 14 | $45.4M |
| Q1 2022 | 14 | $70.6M |
| Q4 2021 | 16 | $152.0M |
| Q3 2021 | 15 | $165.3M |
| Q2 2021 | 20 | $266.2M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Ambrx Biopharma, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Migdal Insurance & Financial Holdings Ltd. | 124 | $1.00K | 0.00% | −76−38.0% | Reduced |
| Bank of America Corp | 131 | $1.00K | 0.00% | +30+29.7% | Added |
| Morgan Stanley | 2,800 | $25.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 11,800 | $107.0K | 0.00% | +11,800 | New |
| Caas Capital Management LP | 13,068 | $118.0K | 0.01% | −26,932−67.3% | Reduced |
| Tudor Investment Corp Et Al | 20,143 | $182.0K | 0.00% | 00.0% | Unchanged |
| Norges Bank | 70,000 | $632.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 98,419 | $889.0K | 0.00% | −43,012−30.4% | Reduced |
| Octagon Capital Advisors LP | 336,868 | $3.04M | 0.59% | −13,132−3.8% | Reduced |
| Suvretta Capital Management, LLC | 1,057,735 | $9.55M | 0.19% | +1,057,735 | New |
| Adage Capital Partners GP, L.L.C. | 1,923,700 | $17.4M | 0.03% | +96,408+5.3% | Added |
| Fosun International Ltd | 1,932,591 | $17.5M | 1.00% | 00.0% | Unchanged |
| Artal Group S.A. | 2,152,291 | $19.4M | 0.57% | +1,302,291+153.2% | Added |
| Cormorant Asset Management, LP | 2,486,386 | $22.5M | 1.34% | 00.0% | Unchanged |
| BlackRock Inc. | 2,869,486 | $25.9M | 0.00% | +2,049,265+249.8% | Added |
| FMR LLC | 3,855,025 | $34.8M | 0.00% | −1,2000.0% | Reduced |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |